Inovio Pharmaceuticals Inc (INO)

[KR_redondo]

There is a conference coming up in the beginning of 2014 called

6th Immunotherapeutics & Immunomonitoring
Jan 29, 2014 to Jan 31, 2014
San Diego, CA, USA

3:30-New Technologies for Improved Vaccines Against Infectious Diseases and Cancer

Jeffrey Ulmer
Global Head, External Research
Novartis
Vaccines are without a doubt the most successful of mankind’s medical interventions. However, despite more than two centuries of effective use of vaccines, many substantial challenges remain. These include: 1) improvement of existing but suboptimal vaccines (e.g., tuberculosis, influenza), 2) discovery and development of new vaccines against targets to address large unmet medical needs (e.g., HIV, malaria, cancer), and 3) rapidly responding to new pathogens (e.g., newly emerging microbes, bioweapons). Recent advancements have demonstrated proof of concept for active immunization in the treatment of cancers. Taking full advantage will require the application of new technologies and paradigms in the areas of tumor antigen identification and optimization, novel potent and safe adjuvants, and enhanced vaccine delivery systems.

3:55-Kate Broderick
Director, Research & Development
Inovio

Kate Broderick is an employee of Inovio, is the one that has been featured in the inovio and novartis recent studies....she's is sharing under the same session as Novartis..note that those are the only two compaines presenting under the title -New Technologies for Improved Vaccines Against Infectious Diseases and Cancer-


yes this conference is early next year, the partnership should be inked before then(just my assumption)here is a link to the conference I am referencing

http://www.gtcbio.com/conference/immunotherapeutics-and-immunomonitoring-agenda#day2


also a Upenn and Novartis relationship has been brewing since last year..I guarantee that Inovio fits in this relationship somewhere we will see soon if my assumptions were right though this is just my opinion, but if you check out the patents coming forward this year by Novartis scientist and the patents by INO you will understand why I believe this partnership will happen(look further into that) on your own time and you will find the connections.


August 6, 2012
Novartis will contribute $20-million to build a center for cancer studies at the University of Pennsylvania, where researchers will try to bring new treatments to market, according to The New York Times. The partnership aims to build on the results of an experimental treatment that manipulates a patient’s immune system to attack cancer cells. Under the terms of an agreement, Penn will grant the Switzerland-based company exclusive rights to the treatment technologies, and the university will receive royalties as well as payments for reaching certain milestones.

Not everything Upenn does has to do with Inovio but when you check out all there work being done you'll see that electroporation is the method all these T-cell treatments are being delivered with(do your DD on that)